



RECEIVED

APR 01 2002

PATENT

Attorney Docket No.: 5565.214-US

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wöldike et al.

Serial No.: 10/044,426

Group Art Unit: To be assigned

Filed: November 13, 2001

Examiner: To be assigned

For: Method For The Production Of VII

**SUPPLEMENTAL PRELIMINARY AMENDMENT  
NO FEE TRANSMITTAL**

Commissioner for Patents  
Washington, DC 20231


Sir:

Transmitted herewith is a Supplemental Preliminary Amendment for the above-identified application.

No fee is required for this Supplemental Preliminary Amendment. Please charge any additional fee to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447.

Respectfully submitted,

Date: February 15, 2002

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 5565.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5B  
3ita  
4-11-02

In re Application of: Jwoldike et al.

Application No.: 10/044,426

Group Art Unit: To be assigned

Filed: November 13, 2001

Examiner: To be assigned

For: Method for the Production of FVII

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

SUPPLEMENTAL PRELIMINARY AMENDMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

Prior to examination of the above-identified application on the merits, kindly amend the application as set forth below.

IN THE CLAIMS:

Cancel claim 6 without prejudice or disclaimer.

Substitute the following claim for original claim 1:

- C  
B
1. (Amended) A method for producing Factor VII comprising (a) cultivation of a mammalian cell line comprising a DNA sequence encoding a yeast-derived endoprotease having Kex2 enzymatic activity and a DNA sequence encoding Factor VII (FVII) in a suitable culture medium, under conditions in which both said endoprotease and said FVII are expressed; and (b) isolation of Factor VII from the medium.

REMARKS

Entry of this amendment is respectfully requested.